These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339 [TBL] [Abstract][Full Text] [Related]
3. NAD as a genotype-specific drug target. Mei SC; Brenner C Chem Biol; 2013 Nov; 20(11):1307-8. PubMed ID: 24267273 [TBL] [Abstract][Full Text] [Related]
4. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase. Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381 [TBL] [Abstract][Full Text] [Related]
5. Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy. Yang P; Zhang L; Shi QJ; Lu YB; Wu M; Wei EQ; Zhang WP Pharmazie; 2015 Oct; 70(10):650-5. PubMed ID: 26601421 [TBL] [Abstract][Full Text] [Related]
6. Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma? Garten A; Schuster S; Penke M Expert Rev Anticancer Ther; 2017 Apr; 17(4):289-291. PubMed ID: 28271737 [No Abstract] [Full Text] [Related]
7. [Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype]. Bertolotto C; Ohanna M; Ballotti R Med Sci (Paris); 2018 Dec; 34(12):1025-1028. PubMed ID: 30623759 [No Abstract] [Full Text] [Related]
8. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in Tateishi K; Higuchi F; Miller JJ; Koerner MVA; Lelic N; Shankar GM; Tanaka S; Fisher DE; Batchelor TT; Iafrate AJ; Wakimoto H; Chi AS; Cahill DP Cancer Res; 2017 Aug; 77(15):4102-4115. PubMed ID: 28625978 [No Abstract] [Full Text] [Related]
9. Apoptosis induced by NAD depletion is inhibited by KN-93 in a CaMKII-independent manner. Takeuchi M; Yamamoto T Exp Cell Res; 2015 Jul; 335(1):62-7. PubMed ID: 26024774 [TBL] [Abstract][Full Text] [Related]
10. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Chen H; Wang S; Zhang H; Nice EC; Huang C Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719 [TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities. Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875 [TBL] [Abstract][Full Text] [Related]
13. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors. Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990 [TBL] [Abstract][Full Text] [Related]
14. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Gujar AD; Le S; Mao DD; Dadey DY; Turski A; Sasaki Y; Aum D; Luo J; Dahiya S; Yuan L; Rich KM; Milbrandt J; Hallahan DE; Yano H; Tran DD; Kim AH Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8247-E8256. PubMed ID: 27930300 [TBL] [Abstract][Full Text] [Related]
15. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening. Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461 [TBL] [Abstract][Full Text] [Related]
16. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859 [TBL] [Abstract][Full Text] [Related]
17. NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview. Pramono AA; Rather GM; Herman H; Lestari K; Bertino JR Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111066 [TBL] [Abstract][Full Text] [Related]
18. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase. Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455 [TBL] [Abstract][Full Text] [Related]
19. Improved synthesis of MC4-PPEA and the biological evaluation of its hydroxymethyl derivative. Sadrerafi K; Zargham EO; Lee MW Bioorg Med Chem Lett; 2016 Jan; 26(2):618-621. PubMed ID: 26681512 [TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT. Wang X; Xu TY; Liu XZ; Zhang SL; Wang P; Li ZY; Guan YF; Wang SN; Dong GQ; Zhuo S; Le YY; Sheng CQ; Miao CY Sci Rep; 2015 Jul; 5():12657. PubMed ID: 26227784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]